Madrigal Pharmaceuticals Inc [MDGL] stock is trading at $437.85, up 0.16%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The MDGL shares have gain 5.59% over the last week, with a monthly amount glided 44.74%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Madrigal Pharmaceuticals Inc [NASDAQ: MDGL] stock has seen the most recent analyst activity on February 28, 2025, when B. Riley Securities upgraded its rating to a Buy and also boosted its price target to $422 from $236. Previously, H.C. Wainwright reaffirmed its Buy rating on February 27, 2025, and elevated its price target to $405. On June 28, 2024, Cantor Fitzgerald initiated with a Neutral rating. Wolfe Research started tracking the stock assigning a Outperform rating and suggested a price target of $382 on June 11, 2024. BofA Securities initiated its recommendation with a Underperform and recommended $150 as its price target on April 22, 2024. B. Riley Securities upgraded its rating to Neutral for this stock on March 15, 2024, and upped its price target to $270. In a note dated March 06, 2024, Citigroup initiated an Buy rating and provided a target price of $382 on this stock.
Madrigal Pharmaceuticals Inc [MDGL] stock has fluctuated between $200.63 and $438.30 over the past year. Currently, Wall Street analysts expect the stock to reach $420 within the next 12 months. Madrigal Pharmaceuticals Inc [NASDAQ: MDGL] shares were valued at $437.85 at the most recent close of the market. An investor can expect a potential drop of -4.08% based on the average MDGL price forecast.
Analyzing the MDGL fundamentals
Madrigal Pharmaceuticals Inc [NASDAQ:MDGL] reported sales of 515.55M for the trailing twelve months, which represents a growth of 1353.76%. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -0.6%, Pretax Profit Margin comes in at -0.55%, and Net Profit Margin reading is -0.55%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.38 and Total Capital is -0.38. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 431.72 points at the first support level, and at 425.59 for the second support level. However, for the 1st resistance point, the stock is sitting at 441.49, and for the 2nd resistance point, it is at 445.13.
Ratios To Look Out For
For context, Madrigal Pharmaceuticals Inc’s Current Ratio is 5.11. Also, the Quick Ratio is 4.78, while the Cash Ratio stands at 0.97. Considering the valuation of this stock, the price to sales ratio is 18.93, the price to book ratio is 13.98.
Transactions by insiders
Recent insider trading involved FRED CRAVES, Former Director, that happened on Aug 29 ’25 when 2900.0 shares were purchased. President and CEO, Sibold William John completed a deal on Aug 21 ’25 to sell 7616.0 shares. Meanwhile, Director WILLIAM SIBOLD bought 7616.0 shares on Aug 21 ’25.
